Anteris Technologies treats first patient in DurAVR heart valve pivotal trial

Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe calcific aortic stenosis. The trial builds on Anteris’ existing clinical data set of 130 patients successfully treated with the DurAVR THV, including de novo aortic stenosis cases, valve-in-valve patients and complex anatomies such as bicuspid aortic valve patients. Anteris aims to drive the global PARADIGM Trial through the addition of further countries and sites in the near term, with planned expansion across the U.S., Europe and Canada.